Cardiac arrhythmias and conduction defects in systemic sclerosis

Alessandra Vacca; Christophe Meune; Jessica Gordon; Lorinda Chung; Susanna Proudman; Shervin Assassi; Mandana Nikpour; Tatiana S Rodriguez-Reyna; Dinesh Khanna; Robert Lafyatis; Marco Matucci-Cerinic; Oliver Distler; Yannick Allanore; Scleroderma Clinical Trial Consortium Cardiac Subcommittee

doi:10.1093/rheumatology/ket377

Cardiac arrhythmias and conduction defects in systemic sclerosis

Rheumatology (Oxford). 2014 Jul;53(7):1172-7. doi: 10.1093/rheumatology/ket377. Epub 2013 Nov 15.

Affiliations

¹ Unit and Chair of Rheumatology, University and A.O.U. of Cagliari, Cagliari, Italy, Cardiology Department, Avicenne Hospital, Bobigny and Cochin Hospital, Paris XIII University, APHP, Paris, France, Department of Rheumatology, Hospital for Special Surgery, New York, NY, Stanford University School of Medicine, Stanford, VA Palo Alto Health Care System, Palo Alto, CA, USA, Rheumatology Unit, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia, Health Science Center at Houston, University of Texas, Houston, TX, USA, St Vincent's Hospital, University of Melbourne, Fitzroy, Melbourne, VIC, Australia, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, Scleroderma Program, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Boston University School of Medicine, Boston, MA, USA, Rheumatology Division, Department of Internal Medicine, University of Florence, Florence, Italy, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland and Rheumatology A Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France.
² Unit and Chair of Rheumatology, University and A.O.U. of Cagliari, Cagliari, Italy, Cardiology Department, Avicenne Hospital, Bobigny and Cochin Hospital, Paris XIII University, APHP, Paris, France, Department of Rheumatology, Hospital for Special Surgery, New York, NY, Stanford University School of Medicine, Stanford, VA Palo Alto Health Care System, Palo Alto, CA, USA, Rheumatology Unit, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia, Health Science Center at Houston, University of Texas, Houston, TX, USA, St Vincent's Hospital, University of Melbourne, Fitzroy, Melbourne, VIC, Australia, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, Scleroderma Program, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Boston University School of Medicine, Boston, MA, USA, Rheumatology Division, Department of Internal Medicine, University of Florence, Florence, Italy, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland and Rheumatology A Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France.Unit and Chair of Rheumatology, University and A.O.U. of Cagliari, Cagliari, Italy, Cardiology Department, Avicenne Hospital, Bobigny and Cochin Hospital, Paris XIII University, APHP, Paris, France, Department of Rheumatology, Hospital for Special Surgery, New York, NY, Stanford University School of Medicine, Stanford, VA Palo Alto Health Care System, Palo Alto, CA, USA, Rheumatology Unit, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia, Health Science Center at Houston, University of Texas, Houston, TX, USA, St Vincent's Hospital, University of Melbourne, Fitzroy, Melbourne, VIC, Australia, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, Scleroderma Program, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Boston University School of Medicine, Boston, MA, USA, Rheumatology Division
³ Unit and Chair of Rheumatology, University and A.O.U. of Cagliari, Cagliari, Italy, Cardiology Department, Avicenne Hospital, Bobigny and Cochin Hospital, Paris XIII University, APHP, Paris, France, Department of Rheumatology, Hospital for Special Surgery, New York, NY, Stanford University School of Medicine, Stanford, VA Palo Alto Health Care System, Palo Alto, CA, USA, Rheumatology Unit, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia, Health Science Center at Houston, University of Texas, Houston, TX, USA, St Vincent's Hospital, University of Melbourne, Fitzroy, Melbourne, VIC, Australia, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, Scleroderma Program, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Boston University School of Medicine, Boston, MA, USA, Rheumatology Division, Department of Internal Medicine, University of Florence, Florence, Italy, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland and Rheumatology A Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France. yannick.allanore@cch.aphp.fr.

Abstract

Signs and symptoms of arrhythmias or conduction defects are frequently reported in patients with SSc. These rhythm disorders may have several origins (i.e., related to primary heart involvement, pericardial disease, valvular regurgitation or pulmonary arterial hypertension) and may negatively affect the overall prognosis of these patients. It is therefore important to identify patients at high risk for cardiac arrhythmias with a complete cardiological evaluation and to identify the underlying heart disease, including SSc-related myocardial involvement. In addition, some therapeutic options in SSc patients may differ from those recommended in other populations.

Keywords: arrhythmias; cardiac involvement; conduction defects; mortality; systemic sclerosis.

Publication types

Review

MeSH terms

Anti-Arrhythmia Agents / therapeutic use
Arrhythmias, Cardiac / drug therapy
Arrhythmias, Cardiac / epidemiology*
Arrhythmias, Cardiac / physiopathology
Electrocardiography
Heart Conduction System / physiopathology*
Humans
Prognosis
Risk Factors
Scleroderma, Systemic / diagnosis
Scleroderma, Systemic / physiopathology*

Substances

Anti-Arrhythmia Agents

Cardiac arrhythmias and conduction defects in systemic sclerosis

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

Grants and funding